Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Polarean Imaging ( (GB:POLX) ) has provided an announcement.
Polarean Imaging has entered into a Representative Agreement with Ascend Imaging to promote and sell its Xenon MRI platform in four US states. This partnership aims to enhance Polarean’s market reach and commercial momentum by leveraging Ascend Imaging’s expertise in radiology and strong customer relationships, supporting Polarean’s strategic expansion in the US market.
The most recent analyst rating on (GB:POLX) stock is a Buy with a £8.00 price target. To see the full list of analyst forecasts on Polarean Imaging stock, see the GB:POLX Stock Forecast page.
More about Polarean Imaging
Polarean Imaging is a medical imaging technology company focused on revolutionizing pulmonary medicine. It specializes in MRI technology for lung function visualization, addressing the needs of over 500 million patients with chronic respiratory diseases. Polarean has developed the FDA-approved XENOVIEW®, a hyperpolarized Xenon MRI inhaled contrast agent, and is committed to advancing non-invasive, radiation-free imaging solutions.
Average Trading Volume: 3,095,122
Technical Sentiment Signal: Sell
Current Market Cap: £16.9M
For an in-depth examination of POLX stock, go to TipRanks’ Overview page.